GDF-15: A novel serum marker for metastases in uveal melanoma patients

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 6, 2012, Pages 887-895

  Suesskind, Daniela ^a   Schatz, Andreas ^a   Schnichels, Sven ^a   Coupland, Sarah E ^b   Lake, Sarah L ^b   Wissinger, Bernd ^a   Bartz Schmidt, Karl U ^a   Henke Fahle, Sigrid ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Metastasis; Serum markers; Uveal melanoma

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHROMOSOME 3; CHROMOSOME NUMBER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHROMOSOMES, HUMAN, PAIR 3; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; IMMUNOHISTOCHEMISTRY; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; UVEAL NEOPLASMS;

EID: 84864322164     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1786-6     Document Type: Article

References (35)

1. Singh AD, Topham A (2003) Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 110:956-961 (Pubitemid 36560496)
2. Shields CL, Shields JA, Cater J, Lois N, Edelstein C, Gündüz K, Mercado G (1998) Transpupillary thermotherapy for choroidal melanoma. Tumor control and visual results in 100 consecutive cases. Ophthalmology 105:581-590 (Pubitemid 28180205)
3. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM (2002) Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 120:1665-1671 (Pubitemid 36401801)
4. Damato B, Groenewald C, McGalliard J, Wong D (1998) Endoresection of choroidal melanoma. Br J Ophthalmol 82:213-218 (Pubitemid 28177106)
5. Verschueren KM, Creutzberg CL, Schalij-Delfos NE, Ketelaars M, Klijsen FL, Haeseker BI, Ligtenberg SM, Keunen JE, Marijnen CA (2010) Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma. Radiother Oncol 95:332-338
6. COMS report no. 15 (2001) Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS). Arch Ophthalmol 119:670-676
7. Seddon JM, Albert DM, Lavin PT, Robinson N (1983) A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 101:1894-1899 (Pubitemid 14249570)
8. Mooy CM, De Jong PT (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41:215-228 (Pubitemid 26424326)
9. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Peér J, Gruman LM (1993) The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100:1389-1398 (Pubitemid 23274035)
10. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222-1225 (Pubitemid 26131850)
11. Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64:7205-7209 (Pubitemid 39372052)
12. Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, Douglas A, Howard P (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114:1925-1931
13. Triozzi PL, Eng C, Singh AD (2008) Targeted therapy for uveal melanoma. Cancer Treat Rev 34:247-258
14. Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T (1999) Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85:1151-1159 (Pubitemid 29115596)
15. Hicks C, Foss AJE, Hungerford JL (1998) Predictive power of screening tests for metastasis in uveal melanoma. Eye 12:945-948 (Pubitemid 29027034)
16. Bootcov M, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. PNAS 94:11514-11519 (Pubitemid 27451030)
17. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, Breit SN (2006) Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66:4983-4986 (Pubitemid 43852864)
18. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF Jr, Hampton GM (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. PNAS 100:3410-3415 (Pubitemid 36356597)
19. Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, Brown DA, Breit SN, Parsons PG (2009) Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 129:383-391
20. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE (2009) Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci 50:3048-3055
21. Malignant melanoma of the uvea, Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A (eds) (2010) AJCC Cancer Staging Manual, 7th edn. Springer, New York, Dordrecht, Heidelberg, London, pp 547-560
22. Schaller UC, Bosserhoff A-K, Neubauer AS, Buettner R, Kampik A, Mueller AJ (2002) Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res 12:593-599 (Pubitemid 36042746)
23. Reiniger IW, Schaller UC, Haritoglou C, Hein R, Bosserhoff AK, Kampik A, Mueller AJ (2005) "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol 243:1161-1166 (Pubitemid 43124169)
24. Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis AJ, Folberg R, Pe'er J (2006) Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 47:802-806 (Pubitemid 46768309)
25. Reiniger IW, Wolf A, Welge-Lüssen U, Mueller AJ, Kampik A, Schaller UC (2007) Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 143:705-707 (Pubitemid 46452513)
26. Barak V, Frenkel S, Kalickman I, Maniotis A, Folberg R, Péer J (2007) Serum markers to detect metastatic uveal melanoma. Anticancer Res 27:1897-1900 (Pubitemid 46954694)
27. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10:2386-2392 (Pubitemid 38445697)
28. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, Breit SN (2003) MIC-1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63:5034-5040 (Pubitemid 37022642)
29. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN (2003) MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 9:2642-2650 (Pubitemid 36842108)
30. Kaiserman I, Amer R, Péer J (2004) Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137:236-243 (Pubitemid 38220994)
31. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ (2000) Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 75:20127-20135 (Pubitemid 30441624)
32. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59:901-908 (Pubitemid 32274020)
33. Ferrari N, Pfeffer U, DelĺEva R, Ambrosini C, Noonan DM, Albini A (2005) The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl) retinamide. Clin Cancer Res 11:4610-4619 (Pubitemid 40825652)
34. Graichen R, Liu D, Sun Y, Lee KO, Lobie PE (2002) Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allows cell cycle progression of human mammary carcinoma cells. J Biol Chem 277:26662-26672 (Pubitemid 34967165)
35. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH (2003) Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648-4655 (Pubitemid 36951043)